Polyphenol, one of the major components that exert the therapeutic effect of Chinese herbal medicine (CHM), comprises several categories, including flavonoids, phenolic acids, lignans and stilbenes, and has long been studied in oncology due to its significant efficacy against cancers in vitro and in vivo. Recent evidence has linked this antitumor activity to the role of polyphenols in the modulation of redox homeostasis (e.g., pro/antioxidative effect) in cancer cells. Dysregulation of redox homeostasis could lead to the overproduction of reactive oxygen species (ROS), resulting in oxidative stress, which is essential for many aspects of tumors, such as tumorigenesis, progression, and drug resistance. Thus, investigating the ROS-mediated anticancer properties of polyphenols is beneficial for the discovery and development of novel pharmacologic agents. In this review, we summarized these extensively studied polyphenols and discussed the regulatory mechanisms related to the modulation of redox homeostasis that are involved in their antitumor property. In addition, we discussed novel technologies and strategies that could promote the development of CHM-derived polyphenols to improve their versatile anticancer properties, including the development of novel delivery systems, chemical modification, and combination with other agents.

Background: New health reform policy of China has gone through more than ten years from 2009 to 2019, it has come a critical period. It is important to evaluate the effect of health system reform policy, but there are a few existing studies and the researchers have not considered the impact of psychological factors on person decision-making. This study using the prospect theory can overcome this defect. Let the evaluation of the effect of new medical reform policy of China more scientific and reasonable. Methods: Data on the effect of the new health reform from China Health Statistics Yearbook and National Bureau of Statistics of China were obtained. And the indicators were selected by Corrected Item Total Correlation and Cronbach’s α reliability coefficient. The selected indicator data were calculated by the prospect theory model. Meanwhile the gray relation analysis method is introduced to enlarge the difference between the advantages and disadvantages to making the comprehensive evaluation result more obvious. Results: The results of comprehensive evaluation of the effects of health reform policies in China fluctuated from 2000 to 2017. From 2000 to 2004, the fluctuation range of the comprehensive prospect value is large; from 2004 to 2009, the comprehensive prospect value shows a slow downward trend; from 2009 to 2012, the comprehensive prospect value has decreased slightly, and then it has rebounded substantially; from 2012 to 2014, the comprehensive prospect value is stable; and from 2014 to 2017, the comprehensive prospect value is declining. Conclusions: This study showed that the implementation of new health reform policy of China has a significant impact on China's medical and health system. The new health reform advanced hard in exploration. It is worth affirming that the overall goal and direction of the new health reform are correct, but the practice is unsatisfactory. The releasing and implementation of supporting policy have the important influence on the progress of the new health reform. And the effect of the policy will decrease with the increase of the total amount. Therefore, scientific and effective late management can ensure that the policy continues to play its role.

Background: Vascular dementia is a common form of dementia which is caused by problems with the blood supply to the brain. Some but not all people with vascular dementia have had strokes. Western medicines licensed to treat vascular dementia are limited. Oral Chinese traditional medicines are often used to treat it in China. Oral Chinese traditional medicine in this review is defined as the oral Chinese Patent Medicine with a certain dosage form of medicinal substances recorded in Chinese materia medica or used in folk medicine. It is a commercial Chinese medicine preparation with standardized in source, nature, collection, processing, dispensing, actions, effects and uses, and approved by the National Health Commission of the People's Republic of China (NHC) and National Medical Products Administration of China (NMPA). Oral Chinese traditional medicines are categorized according to the nature of medicinals (the basic properties of a medicinal). Despite of symptomatic descriptions as 'dementia', 'memory loss', and 'Cognitive deficit' in some of the drug instructions, drug instructions rarely include 'vascular dementia' as one of the indications specifically. However, increasing studies on oral Chinese traditional medicines for the treatment of VaD give thoughts to deliberate about their applications for VaD. Recent studies of oral Chinese traditional medicine have demonstrated in vitro biological activity and therapeutic effects in animals, but the published clinical evidence has not been systematically appraised. INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 19 July 2021 and was last u p d a t e d o n 1 9 J u l y 2 0 2 1 ( r e g i s t r a t i o n n u m b e r INPLASY202170057).